NeurologyLive® Friday 5 — January 7, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peer Exchange: Managing Patients With RRMS on Novel Oral Therapy

In episode 13 of the NeurologyLive^® Peer Exchange, "Oral Therapy Options for Relapsing-Remitting Multiple Sclerosis," Suma Shah, MD, Gabrielle Macaron, MD; and Jennifer Graves, MD, PhD, MAS, discuss the key takeaways from a larger discussion surrounding the utilization of novel oral agents as therapy for patients with relapsing-remitting multiple sclerosis.

2: SAGE Test Detects Early Dementia At Least 6 Months Sooner Than MMSE

Investigators, including Douglas Scharre, MD, also pointed to the potential repetitive administration of the Self-Administered Gerocognitive Examination (SAGE) test to identify stability or decline, effectively providing an objective cognitive biomarker.

3: NeuroVoices: Dejan Jakimovski, MD, PhD, on the Need to Address Cognitive Decline in an Aging MS Population

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed the importance of continued research on how patients with multiple sclerosis experience cognitive decline as they age.

4: Peer Exchange: Optimizing a Diagnostic Work-up of Insomnia

Michael J. Thorpy, MD, ChB; Karl Doghramji, MD; Erinn E. Beagin, MD; Nathaniel Fletcher Watson, MD; and Vikas Jain, MD, FAASM, FAAFP, CCSH, CPE, offer considerations for how to optimally work up and diagnose patients with insomnia in episode 4 of this NeurologyLive^® Peer Exchange, "Unmet Needs in Treating Insomnia."

5: Need for Guidelines on Migraine in Emergency Department Settings

Anne Kelly, MD, director, Joseph Epstein Center for Emergency Medicine Research, detailed the complexities of presenting migraine in the emergency department and why consensus international/national guidelines tailorable to the capabilities of institutions are necessary.

—————————————————

Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

• Nominations are open through January 31, 2022
• The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
• Nominees will be selected on the merits of their lifetime work.
• One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
• The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.